🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI
$24.93
-12.40% 1Y
Mkt Cap$2.41B
P/E-4.28
P/B-30.12
52W High$36.54
52W Low$18.50
Book Value$-0.83
EPS (TTM)$-5.83

Company Overview

RARE (RARE) is a publicly traded company listed on with a market capitalization of $2.41B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 190.4% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $673.00M (+20.2% YoY); net profit $-575.00M.
  • Trailing 12 Months Year-on-year growth — revenue +20.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 190.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:190.42%
1 Year:20.18%

Stock Price Performance

1 Year:-12.40%
6 Months:+0.52%
3 Months:-0.32%
1 Month:-30.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 36% of range
$18.50 $36.54
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.21 · Neutral
Price Performance
1M-30.50%
3M-0.32%
6M+0.52%
1Y-12.40%

Auto-generated from price history and fundamentals; not investment advice.

Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 190.4% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 31.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Ad space

Valuation

Stock P/E
-4.28
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-0.83
Price to Book
-30.12
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
190.42%
Profit 5Y
-
Revenue (YoY)
20.18%
Earnings (YoY)
-

Profitability & Returns

ROCE
-46.60%
ROE
-
ROA
-37.53%
Profit Margin
-85.44%
Op Margin
-79.49%
Gross Margin
83.80%
EPS (Latest Qtr)
$-1.84
EPS (TTM)
$-5.83

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
2.34
Current Ratio
2.48
Debt
$36.00M
Total Assets
$1.30B
Current Assets
$657.00M
Working Capital
$567.00M

Ownership

Promoter Holding
3.45%
Chg in Prom Hold
0.00%
FII / Inst Holding
102.16%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$673.00M
EBITDA
$-474.00M
Free Cash Flow
$-487.00M
Operating Cash Flow
$-466.00M
Shares Outstanding
96.65M
Gross Margin
83.80%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------198.00K2.41M10.68M12.79M11.76M16.26M18.17M24.15M25.80M35.59M36.31M61.71M81.47M91.54M99.39M86.97M81.65M79.94M89.34M90.70M100.50M108.31M98.05M108.83M147.03M139.49M-139.00M166.50M159.93M207.28M136.00M
Cost of Revenue -----------------------------------29.00M23.00M27.99M29.34M30.00M
Gross Profit -----------------------------------110.00M143.49M131.94M177.93M106.00M
Operating Expenses -----------------------------------253.00M251.38M302.83M291.22M275.00M
Operating Income -39.94M--53.62M-58.05M-65.78M--69.95M-78.44M-83.71M--96.49M-94.90M-89.65M--99.21M-112.47M-118.03M--120.67M-63.05M-50.31M--106.57M-82.78M-89.83M-136.63M-141.59M-225.07M-154.10M-147.96M-145.10M-165.35M-116.36M-131.99M--143.00M-107.89M-170.89M-113.28M-169.00M
EBITDA ------------------------------------127.00M-91.35M-156.79M-99.43M-155.00M
Interest Expense -----------------------------------14.00M14.04M14.15M19.47M21.00M
Pretax Income ------------------------------------150.00M-114.00M-179.54M-127.69M-184.00M
Tax Provision -----------------------------------1.00M947.00K873.00K870.00K1.00M
Net Income -39.23M-55.22M-52.76M-56.92M-64.91M-71.29M-68.29M-72.89M-79.23M-81.73M30.25M-52.73M-87.31M-87.83M-96.76M-99.17M-112.99M-93.81M-119.03M25.32M-68.84M-24.01M-136.14M-122.43M-73.00M-152.32M-158.16M-245.11M-163.97M-159.83M-159.65M-170.68M-131.60M-133.52M--151.00M-114.95M-180.41M-128.56M-185.00M
Diluted EPS -------1.63---0.62-1.06-1.74-1.73-1.82-1.72---2.050.41-1.13-0.37--1.81-1.08-2.19-2.26-3.50-2.33-2.25-2.23-2.03-1.52-1.40--1.57-1.17-1.81-1.29-1.84
R&D Expense 29.70M-40.41M43.33M48.71M-51.27M58.44M60.41M-75.50M76.83M70.04M-78.11M96.05M100.14M-112.96M80.71M87.31M-147.52M113.20M113.42M143.16M154.53M237.30M165.70M164.95M157.25M178.49M161.50M170.11M-166.00M164.74M216.21M-187.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ----133.00K2.61M51.49M103.71M271.03M-363.33M434.00M560.00M673.00M
Cost of Revenue ----------28.32M45.00M77.00M109.00M
Gross Profit ----------335.01M389.00M483.00M564.00M
Operating Expenses ----------983.93M958.00M1.02B1.10B
Operating Income -15.98M-32.28M-56.78M-147.74M-248.01M-328.94M-371.37M-424.17M-330.12M--648.92M-569.00M-536.00M-535.00M
EBITDA -----------640.49M-517.00M-468.00M-474.00M
Interest Expense ----------43.02M66.00M63.00M62.00M
Pretax Income -----------701.73M-609.00M-567.00M-571.00M
Tax Provision ----------5.70M-2.00M2.00M4.00M
Net Income -16.33M-35.07M-59.80M-145.62M-245.87M-302.14M-197.61M-402.73M-186.57M--707.42M-607.00M-569.00M-575.00M
Diluted EPS ---------3.07--10.12-8.25-6.29-5.83
R&D Expense 12.64M27.83M45.97M114.74M183.20M231.64M294.00M357.36M412.08M497.15M705.79M648.00M698.00M750.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --59.65M197.97M559.57M540.63M490.75M719.56M1.14B1.76B-1.55B1.49B1.50B1.53B
Current Assets -----------883.90M732.18M817.00M951.00M
Cash & Equivalents 10.64M86.19M7.43M24.32M93.57M161.12M100.49M113.43M433.58M713.53M-132.94M213.58M174.00M421.00M
Inventory -----------26.77M33.97M45.00M52.00M
Receivables -----------40.45M73.39M122.00M158.00M
Total Liabilities --9.54M13.02M28.48M66.65M107.30M110.65M481.73M605.18M-1.19B1.22B1.24B1.60B
Current Liabilities --5.92M12.52M27.92M60.26M71.01M74.72M103.30M189.61M-261.21M280.44M344.00M384.00M
Long Term Debt ---------------
Total Debt -----------31.59M43.17M40.00M36.00M
Total Equity -7.96M-27.05M-74.82M184.94M531.09M473.97M383.45M608.91M653.76M1.15B-352.49M275.41M255.00M-80.00M
Shares Outstanding -----------70.20M82.33M92.55M96.65M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -----160.97M-253.84M-290.57M-345.38M-132.22M--380.46M-475.00M-414.00M-466.00M
Investing Cash Flow ----91.12M55.48M-33.33M-13.04M-179.12M--291.65M168.00M-18.00M236.00M
Financing Cash Flow ----138.68M136.27M336.85M679.31M600.27M-501.21M388.00M399.00M478.00M
Capital Expenditure -1.09M-407.00K-2.15M-4.96M-10.19M-2.79M-4.08M-24.83M-43.91M--146.12M-47.00M-20.00M-21.00M
Free Cash Flow -----171.16M-256.64M-294.64M-370.21M-176.12M--526.59M-522.00M-434.00M-487.00M
Net Change in Cash -----------170.91M81.00M-33.00M248.00M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------92.2%89.6%86.2%83.8%
Operating Margin % -----186,471.4%-12,593.5%-721.2%-409.0%-121.8%--178.6%-131.1%-95.7%-79.5%
Net Margin % -----184,867.7%-11,567.3%-383.7%-388.3%-68.8%--194.7%-139.9%-101.6%-85.4%
ROE % 60.4%46.9%-32.3%-27.4%-51.9%-78.8%-32.5%-61.6%-16.2%--200.7%-220.4%-223.1%718.8%
ROCE % --60.1%-30.6%-27.8%-51.6%-78.4%-57.6%-41.1%-21.0%--50.5%-47.0%-46.2%-46.6%

Shareholding Pattern

Insiders
3.45%
Institutions
102.16%
Public Float
105.82%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RARE

Google News Wed, 05 Aug 2026

Rare Stock Picks In July 2026 - From 22 Discerning Analysts - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPRm5zY0R1VXl4MmhFS01tYTRaS3FQY2NXczhjTXJxRmNacXJYdlFMOHJrYjh5VjZheFF6b0hNbFF2WVpXNDNyMjkzNEFsS1F1eFR2WjBXTnNpY1ZDSWhMRXAwYVM3ZGZUNWxLWFNKR1ZKcEtXY0UtQVlWQXlFdG52MjdvYzR1WG0xWE03Rm…

Google News Wed, 05 Aug 2026

The Nasdaq has flashed a rare bullish signal that suggests a fresh rally is getting ready to kick off - Business Insider

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOM3ZMRHdDN21mRlVKYlRGRWlxaGpCRXRFTHRZbFJiUXN4SlZURmJWRVRoQmt2dExnZ1g0NzBPaWtPYTJUSnFXa3ZXbFVxbDRPdWJ0MThXUmY5RlBfTVpNWmtaOTJWTEpSdjNKeF9fMExXVVZYbE1zX1NrMWNwMlR3b1FlX2g3NkxXSDR3WF…

Google News Mon, 03 Aug 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQV3o5TXdDTmUtM3N6VU56bnY3SkE4dTRkTmlJcU1PLWVIWnB6Ym5tZ3pDVjZXN2hNcjh0SWt5SVZJUmxOektXdkxKX2dxRzRfNHUzTk0yME5qS0pUbklEVmVpbG1yMEdidGxHOXFNY3BwdVVKT3dBZXJUdXdHOUVaTVMxWTRmR2lqZV9GQj…

Google News ue, 04 Aug 2026

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring A 113% Upside Potential - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOV0llVE1YTW9KcV9pVWthS2Y3aUJveGRGTnhMYkxZWktSamlWRlBHSndaQUE0Ql9halVSMERZX3VsMlotSjdTRVNIOTVWcF95amVTLUNJSHIyREQ2eGswM0Nmc1ZoSnB4VVh0M0tmZExET1pjakNOX2djUTctdVhVd3ZWQ0JTUkpldXpjbn…

Google News ue, 04 Aug 2026

Insider Sale: EVP and Chief Legal Officer of $RARE Sells 1,900 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPclhLYWFvbUhsWW9GTzNIazhrSXFGNlplSWVLSnB6bzd3bk1CWkpQMk52N2tocTVObkpXSUlpOVZzV2lPMXRtX2ZRYnB6eW5PNVFsWUgwQ2FvRjc5NHpQcDNtOGRhSVVlcFhZQWFOVGlJdG9sRWIza2F5d1JEZlJ2UWQ4Y2tVODlhYmRyYz…

Google News ue, 04 Aug 2026

FCX Flashes Buy Signal; This Is Fueling Copper, Rare Earth Stocks - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQVVl6QXlKYXpZVUtCaE5aOW9VanR3dnplNE9JZlJQVDdCYXNHTXJDLVRUaG04MjU5NFAtQWhaeWpua1hYUkw5SnNiTDVPRHFmZUtpX0tEQlcyNWFMQnM5WHVoUEhDdzRzZWpBb2dqM0RFSGEtYndNN2lIM0JENVNlUWNYbzl6Nmg2V013OD…

RARE — Frequently Asked Questions

What is the current share price of RARE?

As of 2026-08-05 17:25 PDT, RARE trades at $24.93 on NASDAQ/NYSE. Its 52-week range is $18.50 to $36.54.

What is the market capitalisation of RARE?

RARE has a market capitalisation of $2.41B on NASDAQ/NYSE.

What is the P/E ratio of RARE?

RARE trades at a trailing price-to-earnings (P/E) ratio of -4.28. Its price-to-book (P/B) ratio is -30.12.

Is RARE a good stock to buy?

This page provides a data-driven analysis of RARE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks